APAC Parkinson’s Disease Treatment Market

APAC Parkinson’s Disease Treatment Market Size & Growth (2022 to 2027)

The size of the Asia Pacific Parkinson’s Disease Treatment Market was worth USD 1.04 billion in 2020 and estimated to be growing at a CAGR of 6.79%, to reach USD 1.44 billion by 2025.

The continually increasing number of aging people and increased prevalence of Parkinson's disease are the major factors that are boosting the demand of the Asia Pacific Parkinson's disease treatment market. The development of innovative and novel treatment methods and increasing popularity for minimally invasive surgeries among the people are propelling the growth of the Asia Pacific Parkinson's disease treatment market. The increasing awareness among the people regarding healthcare is also boosting up the growth rate of Parkinson's disease treatment market in the Asia Pacific. The availability of key market players and an increasing number of manufacturers are also contributing to the growth of the APAC Parkinson's disease treatment market.  

An increasing account of the geriatric population and continuously growing patient base are likely to boost the demand for Parkinson's treatments and expand growth opportunities for the stakeholders in the APAC market. Increasing focus on the R&D activities by the private and public organizations for developing novel and innovative treatment methods owing to immense advancements in healthcare are expected to be creating more growth opportunities for the market over the forecast period. Emerging economies of the developed and developing countries such as India, China, Japan and others in the Asia Pacific are expected to create lucrative opportunities for the market players in the region during the forecast period. Patent expiration of many prominent drugs is foreseen to create lucrative opportunities for the key players in the Asia Pacific Parkinson's disease treatment market.

Stringent regulatory rules and policies are the significant challenges to the growth rate of Parkinson's disease treatment market in this area. Unfavorable reimbursement policies are limiting the growth of Asia Pacific Parkinson's disease treatment market. The availability of alternative treatments is a major challenge for the growth of the Asia Pacific Parkinson's disease treatment market and is expected to restrain the market during the forecast period.

This research report on the Asia Pacific Parkinson’s Disease Treatment Market has been segmented and sub-segmented into the following categories:

By Drug Class: 

• Dopamine Receptor Antagonists

  • Pramipexole

  • Ropinirole

  • Apomorphine

  • Rotigotine

• Mono Amine Oxidase Inhibitors

  • Selegiline

  • Rasagiline

• Carbidopa

• Anticholinergics

• Other Drug Classes

By Distribution Channels: 

• Retailer Pharmacies

• Hospital Pharmacies

• Online Pharmacies

By Patient Care Setting:

• Clinics

• Hospitals 

By Country:

• India

• China

• Japan

• South Korea

• Australia

• New Zealand

• Thailand

• Malaysia

• Vietnam

• Philippines

• Indonesia

• Singapore

• Rest of APAC

Regionally, Asia Pacific region is expected to have the fastest growth rate during the forecast period, owing to the huge population base in the region.

Key market participants leading the APAC Parkinson’s Disease Treatment Market profiled in this report are Teva (Israel), Novartis AG (Switzerland), GSK (UK), AbbVie (US), Merck (US), Boehringer Ingelheim (Germany), Impax Laboratories (US), Lundbeck (Denmark), Sun Pharma (India), Wockhardt (India), UCB (Belgium), Valeant Pharmaceuticals (Canada), and Acadia (US).